D-Rev Brilliance Pro


A phototherapy device to treat neonatal jaundice

Content Partner:

Product description Brand name and product description

D-Rev’s Brilliance Pro is a blue LED-based phototherapy device for treatment of neonatal jaundice with an integrated light meter, the latest model in their line of phototherapy devices.

Target region(s) Target region for distribution/implementation (listed by country if specified)

Countries Targeted: Colombia, Ecuador, Guyana, India, Kenya, Malawi, Malaysia, Myanmar, Nepal, Nigeria, Pakistan, Philippines, South Africa, Tanzania, Thailand, Uganda

Distributors/implementing organizations Organization(s) distributing/deploying this product directly to communities/individuals?"

Phoenix Medical Systems Private Ltd in Chennai India manufactures, distributes, and sells Brilliance under a license from D-Rev.

“D-Rev listens to customers and works with Phoenix so the product and manufacturing capabilities are aligned; it is a true partnership. The cooperation will create more products at affordable costs, and be a catalyst for market-change,” said Sashi Kumar, managing director of Phoenix Medical Systems.

Market suggested retail price Price per unit or service price per usage/terms (USD). Subsidies noted.

While the base retail price with 1-year warranty is marked as $400 USD, the official press release on the launch of Brilliance Pro states that the product is available at a price point of $500 USD. This may be because of a licensing agreement between D-Rev and their distributor Phoenix Medical Systems Private Ltd that caps the selling price of Brilliance products in emerging and undercapitalized markets at $400 USD. Therefore, the price may differ based on the target market.

Competitive landscape Similar products available on the market. May not be a comprehensive listing.

A variety of phototherapy devices have been designed for the treatment of neonatal jaundice. An overview includes competitors such as DtM FireflyMedela BilibedDraeger Photo-TherapyNatus neoBLUE, and Delta TL.

SDG targeted United Nations Sustainable Development Goals (SDGs) targeted with this product/application/service

Goal 3: to improve and promote good health.Newborns with mild to severe jaundice. Jaundice is the #1 reason why newborns are readmitted to hospitals worldwide. About 3 in 5 children have some degree of jaundice. Severe jaundice, when left untreated or ineffectively treated, can lead to severe brain damage or death. Studies estimate that over 6 million babies with severe jaundice are not receiving adequate treatment.

Target user(s) Target user/consumer base (country, income segment)

Hospitals and clinics with neonatal intensive care units (NICUs) or special newborn care units (SNCUs) in developing countries.

The @AutodeskFdn blogged about our how-to guide for communities writing proposals for development projects https://t.co/MlRH1H0x2F